Press Releases

 
Press Releases
Date Title and Summary View
Feb 16, 2016 BOSTON, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will participate in two upcoming investor conferences: ...
Feb 2, 2016 BOSTON, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, announced today that it will present at two upcoming investor conferences: The ...
Jan 20, 2016 - bestPWS Study is the first Phase 3 pivotal trial to show significant weight-loss and improve hyperphagia-related behaviors in PWS patients- -Statistically significant at both 2.4 mg and 1.8 mg dose levels- -Company plans to discuss results and path forwa...
Dec 2, 2015 BOSTON, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today received verbal notice from the U.S. Food and Drug Administration (FDA) that its beloranib investi...
Dec 2, 2015 BOSTON, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today provided an update on the open label extension (OLE) portion of the pivotal Phase 3 ZAF-311 bestPW...
Nov 10, 2015 Company to Host Conference Call at 4:30 PM Eastern Time to Review Progress with Beloranib Program Ends Quarter with Cash, Cash Equivalents and Marketable Securities of $204 Million; Increases Year-End Cash Guidance to Greater than $180 Million BOSTON, Nov....
Nov 3, 2015 BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it will host a conference call on Tuesday, November 10, 2015 at 4:30 p.m. ET to dis...
Oct 22, 2015 -Company Elects to Proceed with Data Analysis for the Pivotal Phase 3 Study in Prader-Willi Syndrome and the Phase 2b in Severe Obesity Complicated by Type 2 Diabetes-  -Open Label Extension Portion of Phase 3 Prader-Willi Syndrome Study to Continue- BOSTON, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical c...
Oct 16, 2015 BOSTON, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today announced that it received verbal notice late yesterday from the U.S. Food and Drug Administration (FDA) that belora...
Oct 14, 2015 BOSTON, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, today issued the following statement: "Zafgen recently learned of a patient death which occurred in the Compa...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase